AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
treatment of inflammatory bowel disease (IBD), from the Chinese biotech FutureGen Biopharmaceutical. IBD includes two conditions, Crohn's disease (CD) and ulcerative colitis (UC), both characterized by chronic inflammation in the gastrointestinal tract. FG-M701, a novel TL1A inhibitor, is in pre-clinical development. It has been developed by FutureGen leveraging its Structure-based Targeted Evolution Platform technology platform. These next-generation IBD therapies are developed to drive greater efficacy and less frequent dosing than the first-generation TL1A antibodies. TL1A is a clinically validated target in IBD treatment. For the deal, AbbVie will pay $150 million in upfront and near-term milestone payments to FutureGen, with the latter also being entitled to an additional $1.56 billion in potential milestone payments plus tiered royalties on net sales if the product is ultimately approved. The deal will strengthen AbbVie's inflammatory and autoimmune disease portfolio, whic
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Direct Relief Announces Appointment of Three Directors to Board [Yahoo! Finance]Yahoo! Finance
- AbbVie Declares Quarterly DividendPR Newswire
- Top 10 Companies Dominating the Global Drug Delivery Systems Market [Yahoo! Finance]Yahoo! Finance
- Cosmetic Surgery and Procedure Devices Market size is set to grow by USD 7.95 billion from 2024-2028, Growing incidence of medical conditions that require cosmetic procedures boost the market, Technavio [Yahoo! Finance]Yahoo! Finance
- MHRA disallows epilepsy drug topiramate use for pregnant patients [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 4/26/24 - Miss
ABBV
Sec Filings
- 6/3/24 - Form 25-NSE
- 5/31/24 - Form SD
- 5/17/24 - Form 25-NSE
- ABBV's page on the SEC website